These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25482382)

  • 1. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
    Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
    Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
    Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
    PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers.
    Arellano-Rodrigo E; Lopez-Vilchez I; Galan AM; Molina P; Reverter JC; Carné X; Villalta J; Tassies D; Lozano M; Díaz-Ricart M; Escolar G
    Transfus Med Rev; 2015 Oct; 29(4):242-9. PubMed ID: 26364029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
    Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
    Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
    Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
    Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Anticoagulation Activity of Apixaban.
    Gonçalves LR; Araújo F
    Circ J; 2015; 79(7):1641. PubMed ID: 26028321
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of the Anticoagulation Activity of Apixaban--Reply.
    Silvain J
    Circ J; 2015; 79(7):1642. PubMed ID: 26028322
    [No Abstract]   [Full Text] [Related]  

  • 10. Measuring and reversing the effect of non-vitamin K antagonist oral anticoagulants (NOACs).
    Silvain J; Hauguel M; Kerneis M; Collet JP; Montalescot G;
    Circ J; 2015; 79(2):289-91. PubMed ID: 25744745
    [No Abstract]   [Full Text] [Related]  

  • 11. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
    Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
    Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
    Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
    Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates.
    Caballo C; Escolar G; Diaz-Ricart M; Lopez-Vílchez I; Lozano M; Cid J; Pino M; Beltrán J; Basora M; Pereira A; Galan AM
    Blood Transfus; 2013 Jul; 11(3):391-9. PubMed ID: 23058866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
    Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
    Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Thromb J; 2017; 15():6. PubMed ID: 28239301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
    Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
    Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.